Precision Medicine

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.

A new biotech partnership is accelerating development of a once-daily tablet for hypoparathyroidism, a rare disease currently requiring injections.

Celcuity prepares for a key fireside chat at Guggenheim's 2026 summit, with investors eyeing crucial updates on its lead cancer drug, gedatolisib.

With promising new pipeline data and a major earnings report looming, Aclaris Therapeutics heads to two investor summits, placing its strategy on display.

Following promising early results, RESTEM's Restem-L cell therapy enters a pivotal Phase 2/3 trial, aiming to transform treatment for IIM patients.

Precision medicine firm Atropos Health joins NY's elite digital health startups, signaling a market shift toward scalable, data-driven healthcare solutions.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

An independent analysis shows a specialized OB/GYN staffing model improves maternal outcomes, lowers C-section rates, and delivers a significant return on investment.

Current blood thinners carry a risky trade-off. A new class of drugs targeting Factor XIa could prevent deadly clots without the dangerous bleeding.

Industrial giant AMETEK acquires LKC Technologies, aiming to revolutionize eye care with portable diagnostic devices for early disease detection.

Relay Therapeutics' experimental drug, zovegalisib, offers new hope for a common and hard-to-treat form of advanced breast cancer with a promising safety profile.

A New Mexico health system is betting on a full-scale AI rollout to reduce doctor burnout, improve patient care, and boost its bottom line.

Pharming Group projects strong 2026 growth, fueling ambitious clinical programs for rare immunodeficiencies and mitochondrial diseases.

Death rates fall, but a new report reveals rising incidence and stark inequities. Can new drugs and AI reshape the future for all patients?

Amid rising drug price scrutiny, Red Nucleus acquires an AI-powered consultancy to revolutionize how biopharma proves the value of new medicines.

As AI systems deny healthcare claims at alarming rates, experts argue that human oversight is the only safeguard for both patients and payors.

Praxis and SEQSTER expand their alliance, leveraging a powerful data platform to speed up development of new treatments for epilepsy and other CNS disorders.

A new liquid biopsy more accurately predicts cancer recurrence than standard methods, offering new hope and clarity for patients after surgery.

vTv Therapeutics shores up its finances with a deal worth up to $135M, sharpening its focus on a breakthrough Type 1 diabetes drug, cadisegliatin.

At MD&M West 2026, Boyd showcases how materials science and regulatory expertise are the unsung heroes behind the next wave of medical wearables.